President Donald Trump’s administration has finalized a nationwide rule ending federal Medicaid and Children’s Health Insurance Program funding for puberty blockers, cross-sex hormones and gender-transition surgeries provided to minors.
And no, this is not merely about a handful of surgeries, as some early headlines suggested.
The considerably broader rule covers Medicaid patients younger than 18 and CHIP beneficiaries younger than 19. It takes effect October 13, although children already receiving hormone therapy can receive federally funded coverage for up to six additional months while tapering off treatment. Mental-health services remain covered.
The regulation does not make the treatments illegal. States determined to continue covering them may do so with their own money—but Washington will no longer help pick up the tab. CMS described the change as applying exclusively to federal Medicaid and CHIP funding.
Trump did not impose a national criminal ban. He told states that if they want these controversial interventions for children, they can explain the decision—and the bill—to their own taxpayers.
“Today, we are ending federal taxpayer funding for sex-rejecting procedures on children,” Health and Human Services Secretary Robert F. Kennedy Jr. announced.
CMS Administrator Dr. Mehmet Oz was equally direct. “Children deserve our protection, not experimental interventions that pose serious risks and convey no proven benefits,” Oz said.
President Trump celebrated the decision on Truth Social, saying Americans should not be forced to finance what he called “barbaric surgeries and practices” carrying the possibility of “unthinkable and irreversible harm.” “Just think about all of the young, innocent and perhaps confused children who will be spared,” Trump wrote.
Trump accused Democrats of supporting the removal of children’s reproductive organs before those children are old enough to vote, declaring that he and the Republican Party would “protect America’s children.” He urged voters to remember the issue when casting ballots in November’s midterm elections.
The administration says its decision followed a review of American and international research, including Britain’s Cass Review, which identified serious weaknesses in the evidence supporting medical transition treatments for children.
CMS contends that puberty blockers, cross-sex hormones and surgeries may produce long-term consequences involving fertility, sexual function and bone development. The agency says the available evidence does not justify requiring federal taxpayers to fund the treatments.
Critics vigorously dispute that assessment. Organizations including the American Academy of Pediatrics and American Medical Association maintain that treatment decisions should be made individually by patients, parents and physicians.
That is the familiar “leave it to families and doctors” argument. But once Medicaid money enters the examination room, taxpayers enter with it. The question is no longer simply what a physician may provide. It is what the federal government must subsidize.
The rule is expected to reduce combined federal and state Medicaid spending by approximately $235 million over ten years, including an estimated $138 million in federal funds. CMS acknowledged that the policy was not designed primarily as a budget-cutting measure, according to Reuters. In other words, this is a policy judgment, not an exercise in balancing Washington’s hopelessly bloated checkbook.
The Human Rights Campaign immediately denounced the decision.
“Every young person is entitled to the health care that they, their parents, and their medical providers agree that they need,” HRC President Kelley Robinson said, accusing the administration of “terrorizing trans youth and their families.”
That reaction previews the courtroom battle to come. Democratic attorneys general previously sued over an earlier version of the policy, arguing that the administration was exceeding federal authority, interfering with state regulation of medicine and attempting to create a national medical standard through Medicaid financing.
The finalized rule relies partly on a Medicaid statute directing federal officials to act in beneficiaries’ “best interests.” Opponents call that interpretation novel and legally vulnerable. Supporters will argue that Washington has both the authority and responsibility to decide which procedures qualify for federal reimbursement.
Fourteen states and the District of Columbia have enacted shield laws protecting access to gender-transition treatments. Those jurisdictions will now face a choice: end Medicaid and CHIP coverage for the affected procedures or finance them without federal matching funds.
Lawsuits are not merely possible. They are as certain as activists discovering the courthouse whenever voters or elected officials reject their agenda.
Still, the political ground has changed. In 2025, the Supreme Court upheld Tennessee’s restrictions on gender-transition treatments for minors against an equal-protection challenge. That decision did not automatically validate every federal funding restriction, but it demolished the claim that every limitation is self-evidently unconstitutional. KFF reports that 27 states now have laws or policies restricting minors’ access to these treatments.
Supporters of pediatric gender medicine frequently note that medical transition treatments remain “uncommon” among minors.
A study examining insurance claims for more than five million patients between eight and 17 found that 926 adolescents with gender-related diagnoses received puberty blockers between 2018 and 2022, while 1,927 received hormones. Gender-transition surgeries among younger minors are rarer still. But the “rareness” claim itself is subjective. And an irreversible procedure does not become wise, evidence-based or deserving of federal subsidy merely because relatively few children receive it. Nor does the word “care” magically resolve every dispute about safety, evidence and informed consent. Medicine has reversed course before—sometimes after confidently assuring the public that the experts had spoken and the debate was over.
International health authorities have become increasingly cautious about pediatric medical transition. The United Kingdom restricted routine prescribing of puberty blockers after the Cass Review, and several European health systems have moved toward more conservative treatment protocols.
American activists, meanwhile, often behave as though asking for long-term evidence is itself an act of cruelty.
Trump announced the final rule less than three months before the midterm elections and explicitly told Americans to vote with the policy in mind.
Republicans now have a clean argument, adults remain free to make their own medical decisions, but taxpayers should not be compelled to finance life-altering transition treatments for children when the long-term evidence remains fiercely contested.
Democrats must decide whether to fight on that terrain. They can argue that parents, physicians and children should control treatment without interference—or explain why taxpayers in states that reject these procedures must continue subsidizing them elsewhere.
WIRE SOURCES
- CMS ends federal Medicaid and CHIP funding for “sex-rejecting procedures” for children and youth
- U.S. bars federal funding of gender-affirming care for low-income minors
- Medicaid to stop funding child transition hormones and surgeries
- KFF tracker: State restrictions on youth gender-affirming care
- Trump executive order on medical transition procedures for minors
